Could Mereo Biopharma Group Plc ADR (MREO)’s Current Volatility Hinder Its Future Potential?

Mereo Biopharma Group Plc ADR (NASDAQ:MREO) has a beta value of 0.89 and has seen 2.43 million shares traded in the recent trading session. The company, currently valued at $521.10M, closed the recent trade at $3.71 per share which meant it gained $0.19 on the day or 5.54% during that session. The MREO stock price is -17.52% off its 52-week high price of $4.36 and 71.16% above the 52-week low of $1.07. The 3-month trading volume is 942.82K shares.

Mereo Biopharma Group Plc ADR (NASDAQ:MREO) trade information

Sporting 5.54% in the green today, the stock has traded in the green over the last five days, when the MREO stock price touched $3.71 or saw a rise of 11.24%. Year-to-date, Mereo Biopharma Group Plc ADR shares have moved 60.82%, while the 5-day performance has seen it change 6.14%. Over the past 30 days, the shares of Mereo Biopharma Group Plc ADR (NASDAQ:MREO) have changed 25.08%.

3 Tiny Stocks Primed to Explode The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.

We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.

Click here for full details and to join for free
Sponsored

Mereo Biopharma Group Plc ADR (MREO) estimates and forecasts

Figures show that Mereo Biopharma Group Plc ADR shares have outperformed across the wider relevant industry. The company’s shares have gained 86.68% over the past 6 months, with this year growth rate of 115.00%, compared to 15.40% for the industry.

If we evaluate the company’s growth over the last 5-year and for the next 5-year period, we find that annual earnings growth was 41.78% over the past 5 years.

MREO Dividends

Mereo Biopharma Group Plc ADR is expected to release its next earnings report in July this year, and investors are excited at the prospect of better dividends despite the company’s debt issue.